Deyaa Adib, M.D. has over 28 years of experience in the biotechnology and pharmaceutical industries in multidisciplinary oncology and immuno-oncology from drug research, through commercialization experience with 7 global registrations including Taxotere, Eloxatin, Xtandi, Oncaspar, Tazverick, Onivyde and Eclusig in multiple indications across hematologic malignancies and solid tumors. Currently serving as the Chief Medical Officer at AffyImmune advancing a CAR-T cell therapy program towards registration in anaplastic thyroid cancer via successful FDA interactions and financing rounds.
Previously, he served as SVP & Chief Medical Officer at FibroGen (NASDAQ FGEN) leading the development of late stage 1st in class mAB (CTGF) and an ADC (CD46) in pancreatic cancer and prostate cancer indications and previously the CMO for Triumvira Immunologics leading the development of early and mid stage TCR (TAC-T) autologous cell therapies for multiple targets in GI solid tumors and securing multiple financing rounds. Dr. Adib served as Acting CMO at Rain Therapeutics advancing the organization from the private into public sector via licensing deals leading to a successful IPO.
Before that, he was the Vice President of late-stage development at Blueprint Medicines advancing the devleopment of avaprinitnib towards registration in GIST. Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta building the oncology portfolio from the ground up and advancing the development of nano-liposomal irinotecan towards approval in pancreatic cancer, pegasparage in ALL and securing multiple licensing/M&A opportunities in the I-O space leading to the acquisition by Shire for 11.2 Billion for the oncology portfolio. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals repositioning ponatinib & brigatinib from local into global domain hence, securing the acquisition by Takeda for 5.2 Billion . Earlier in his career, he held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma. Dr. Adib obtained an M.B., B.Ch. (M.D.) degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation. He completed his research fellowship in cancer immunology at St. Joseph’s Hospital & Medical Center in Paterson, New Jersey.
Deyaa Adib, M.D. has over 28 years of experience in the biotechnology and pharmaceutical industries in multidisciplinary oncology and immuno-oncology from drug research, through commercialization experience with 7 global registrations including Taxotere, Eloxatin, Xtandi, Oncaspar, Tazverick, Onivyde and Eclusig in multiple indications across hematologic malignancies and solid tumors. Currently serving as the Chief Medical Officer at AffyImmune advancing a CAR-T cell therapy program towards registration in anaplastic thyroid cancer via successful FDA interactions and financing rounds.
Previously, he served as SVP & Chief Medical Officer at FibroGen (NASDAQ FGEN) leading the development of late stage 1st in class mAB (CTGF) and an ADC (CD46) in pancreatic cancer and prostate cancer indications and previously the CMO for Triumvira Immunologics leading the development of early and mid stage TCR (TAC-T) autologous cell therapies for multiple targets in GI solid tumors and securing multiple financing rounds. Dr. Adib served as Acting CMO at Rain Therapeutics advancing the organization from the private into public sector via licensing deals leading to a successful IPO.
Before that, he was the Vice President of late-stage development at Blueprint Medicines advancing the devleopment of avaprinitnib towards registration in GIST. Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta building the oncology portfolio from the ground up and advancing the development of nano-liposomal irinotecan towards approval in pancreatic cancer, pegasparage in ALL and securing multiple licensing/M&A opportunities in the I-O space leading to the acquisition by Shire for 11.2 Billion for the oncology portfolio. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals repositioning ponatinib & brigatinib from local into global domain hence, securing the acquisition by Takeda for 5.2 Billion . Earlier in his career, he held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma. Dr. Adib obtained an M.B., B.Ch. (M.D.) degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation. He completed his research fellowship in cancer immunology at St. Joseph’s Hospital & Medical Center in Paterson, New Jersey.
Don is a serial entrepreneur. He has founded or co-founded 14 companies, three political non-profits and one of the largest private schools in Texas, Regents School of Austin. He currently serves as Chairman and CEO of PJS of Texas, Inc. which he founded 36 years ago. PJS is one of the largest privately-owned commercial cleaning companies in Texas employing over 4,000 people. He also serves on the board of Core Fellowship. Don received his bachelors degree from Western Washington University and continued his graduate studies at Dallas Theological Seminary.
Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.
Jim has been with Aminex since 2012. He was one of six top executives with NASA’s Apollo lunar landing program management, and he has spent almost 40 years in several corporate leadership positions in high-tech electronics systems, heavy infrastructure maintenance equipment manufacturing, and biotech drug development. Jim is retired chairman of Alamo Group, Inc. (NYSE) Prior to that, as chairman, CEO, and president of Tracor Inc., he led the turnaround and six times growth of Tracor in the defense electronics industry with 10,000 employees. Tracor was a Fortune 100 Fastest Growing Company. Jim graduated with a bachelor’s degree in mechanical engineering from the University of Washington and has received numerous honorary awards.